System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for...

Area of Science:

• Hepatocellular Carcinoma Research
• Cancer Immunology
• Molecular Oncology

Background:

• Monotherapy with immune checkpoint inhibitors shows limited efficacy in advanced hepatocellular carcinoma (HCC).
• Combination therapies demonstrate superior outcomes, highlighting the need for novel combination targets.
• Identifying new targets is crucial for improving HCC treatment strategies.

Purpose of the Study:

• To identify novel immunosuppressive targets in HCC amenable to combination therapy.
• To investigate the role of zinc finger protein 207 (ZNF207) in regulating HCC immunity.
• To evaluate the therapeutic potential of targeting ZNF207 in conjunction with anti-PD1 therapy.

Main Methods:

• Integrated cancer-immunity cycle scoring, weighted gene coexpression network analysis, and system analyses to screen targets.
• In vitro and in vivo experiments to assess ZNF207's impact on HCC immunity.
• RNA sequencing, metabolomics, cytokine arrays, and molecular assays to elucidate ZNF207's regulatory mechanisms.

Main Results:

• ZNF207 was identified as a key immunosuppressive target in HCC.
• Hypoxia-induced ZNF207 upregulation promoted HCC progression, decreased CD8+ T-cell infiltration, and increased T-cell exhaustion.
• ZNF207 regulates CD8+ T-cell chemotaxis via the MAPK-CX3CL1 axis and induces T-cell exhaustion by upregulating IDO1.
• Lower ZNF207 expression correlated with better response to anti-PD1 therapy.

Conclusions:

• ZNF207 plays a significant role in suppressing the HCC immune microenvironment.
• Targeting ZNF207 is a feasible strategy to enhance the efficacy of anti-PD1 therapy in HCC.
• Silencing ZNF207 may improve outcomes for patients undergoing anti-PD1 combination therapy.